EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform…


Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance - as part of the InnoBio investment strategy.

Go here to read the rest:
EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform...

Related Posts